1
|
Hernanz N, Rodríguez de Santiago E, Marcos Prieto HM, Jorge Turrión MÁ, Barreiro Alonso E, Rodríguez Escaja C, Jiménez Jurado A, Sierra M, Pérez Valle I, Volpato N, García Prada M, Nuñez-Gómez L, Ríos-León R, Castaño García A, García de Paredes AG, Aicart M, Caminoa A, Peñas Parcía B, Vázquez-Sequeiros E, Albillos A. Characteristics and consequences of missed gastric cancer: A multicentric cohort study. Dig Liver Dis 2019; 51:894-900. [PMID: 30898522 DOI: 10.1016/j.dld.2019.02.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 02/09/2019] [Accepted: 02/11/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Missed gastric cancer (MGC) is poorly documented in Mediterranean populations. AIMS (1) To assess the rate, predictors and survival of MGC. (2) To compare MGC and non-MGC tumors. METHODS This is a retrospective-cohort study conducted at four centers. MGC was defined as cancer detected within three years after negative esophagogastroduodenoscopy. Gastric adenocarcinomas diagnosed between 2008-2015 were included. Patients with no follow-up were excluded. RESULTS During the study period 123,395 esophagogastroduodenoscopies were performed, with 1374 gastric cancers being diagnosed (1.1%). A total of 1289 gastric cancers were finally included. The overall rate of MGC was 4.7% (61/1289, 3.7-6%). A negative esophagogastroduodenoscopy in MGC patients was independently associated with PPI therapy (p < 0.001), previous Billroth II anastomosis (p = 0.002), and lack of alarm symptoms (p < 0.001). The most frequent location for MGC was the gastric body(52.4%). MGCs were smaller than non-MGCs (31 vs 41 mm, p = 0.047), more often flat or depressed (p = 0.003) and less likely to be encountered as advanced disease. Overall 2-year survival was similar between MGC (34.1%) and Non-MGC (35.3 %) (p = 0.59). CONCLUSION MGC accounted for nearly five percent of newly-diagnosed gastric adenocarcinomas. Overall survival was poor and not different between MGC and non-MGC.
Collapse
Affiliation(s)
- Nerea Hernanz
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Enrique Rodríguez de Santiago
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS),Spain.
| | | | | | | | - Carlos Rodríguez Escaja
- Department of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Spain
| | - Andrea Jiménez Jurado
- Gastroenterology department, Hospital Universitario de Salamanca, University of Salamanca, IBSAL, Spain
| | - María Sierra
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | | | - Nadja Volpato
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - María García Prada
- Gastroenterology department, Hospital Universitario de Salamanca, University of Salamanca, IBSAL, Spain
| | - Laura Nuñez-Gómez
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Raquel Ríos-León
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Andrés Castaño García
- Gastroenterology department, Hospital Universitario de Salamanca, University of Salamanca, IBSAL, Spain
| | - Ana García García de Paredes
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Marta Aicart
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Alejandra Caminoa
- Department of Pathology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain
| | - Beatriz Peñas Parcía
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS),Spain
| | - Enrique Vázquez-Sequeiros
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS),Spain
| | - Agustín Albillos
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcala, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS),Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Spain
| |
Collapse
|
2
|
Bermejo San José F, Algaba A, López Durán S, Guerra I, Aicart M, Hernández-Tejero M, Garrido E, de Lucas M, Bonillo D, López Sanromán A. Mercaptopurine and inflammatory bowel disease: the other thiopurine. Rev Esp Enferm Dig 2017; 109:10-16. [PMID: 27809554 DOI: 10.17235/reed.2016.4546/2016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Data about use and effectiveness of mercaptopurine in inflammatory bowel disease are relatively limited. AIMS To assess the possible therapeutic indications, efficacy and safety of mercaptopurine as an alternative to azathioprine in inflammatory bowel disease. METHODS Retrospective observational study in patients treated with mercaptopurine in a total cohort of 1,574 patients with inflammatory bowel disease. RESULTS One hundred and fifty-two patients received mercaptopurine, 15.7% of these patients as an initial thiopurine, 5.3% after azathioprine failure, and 79% after azathioprine intolerance. In 52.6% of patients (n = 80), adverse effects of mercaptopurine occurred, resulting in withdrawal in 49 of them. Mercaptopurine was effective in 39% of cases (95% CI 31-48%). In the remaining patients, failure was due mainly to withdrawal due to side effects (55.1%) and therapeutic step-up (33.7%). The average total time of mercaptopurine exposure was 36 months (IQR: 2-60). Myelotoxicity with mercaptopurine was more common in patients with intermediate TPMT activity than in those with normal activity (p = 0.046). CONCLUSIONS In our setting, mercaptopurine is primarily used as a rescue therapy in patients with azathioprine adverse effects. This could explain its modest efficacy and the high rate of adverse effects. However, this drug is still an alternative in this group of patients, before a therapeutic step-up to biologics is considered.
Collapse
Affiliation(s)
| | | | - Sergio López Durán
- Servicio de Gastroenterología, Hospital Universitario Ramón y Cajal, España
| | - Iván Guerra
- Digestivo, Hospital Universitario de Fuenlabrada
| | - Marta Aicart
- Gastroenterologia, Hospital Universitario Ramón y Cajal
| | | | - Elena Garrido
- Gastroenterología, Hospital Universitario Ramón y Cajal
| | | | | | | |
Collapse
|
3
|
Sancho L, Téllez L, Cuño JL, Aicart M, López-Sanromán A. [Corticosteroids and gastroprotection]. Gastroenterol Hepatol 2014; 37:49-50. [PMID: 24309483 DOI: 10.1016/j.gastrohep.2013.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2013] [Accepted: 02/18/2013] [Indexed: 06/02/2023]
Affiliation(s)
- Lorena Sancho
- Servicio de Aparato Digestivo, Hospital Universitario Río Hortega, Valladolid, España.
| | - Luis Téllez
- Servicio de Aparato Digestivo, Hospital Ramón y Cajal, Valladolid, España
| | - José Luis Cuño
- Servicio de Aparato Digestivo, Hospital Ramón y Cajal, Valladolid, España
| | - Marta Aicart
- Servicio de Aparato Digestivo, Hospital Ramón y Cajal, Valladolid, España
| | | |
Collapse
|